Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000794557 | SCV000933972 | uncertain significance | Orofacial-digital syndrome IV; Joubert syndrome 18 | 2021-08-24 | criteria provided, single submitter | clinical testing | This sequence change replaces serine with asparagine at codon 399 of the TCTN3 protein (p.Ser399Asn). The serine residue is highly conserved and there is a small physicochemical difference between serine and asparagine. This variant is present in population databases (rs768285987, ExAC 0.003%). This variant has not been reported in the literature in individuals affected with TCTN3-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003243300 | SCV003942906 | uncertain significance | Inborn genetic diseases | 2023-06-01 | criteria provided, single submitter | clinical testing | The c.1196G>A (p.S399N) alteration is located in exon 10 (coding exon 10) of the TCTN3 gene. This alteration results from a G to A substitution at nucleotide position 1196, causing the serine (S) at amino acid position 399 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV000794557 | SCV005678463 | uncertain significance | Orofacial-digital syndrome IV; Joubert syndrome 18 | 2024-05-08 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004740452 | SCV005362411 | uncertain significance | TCTN3-related disorder | 2024-09-29 | no assertion criteria provided | clinical testing | The TCTN3 c.1196G>A variant is predicted to result in the amino acid substitution p.Ser399Asn. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0054% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |